CLINICAL TRIAL: CHRONIC LYMPHOCYTIC LEUKEMIA

这个子项目是众多研究子项目之一

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chronic lymphocytic leukemia is rarely curative disease. Novel treatments are needed. Like many other malignancies, tumor suppressor genes may be silenced by DNA methylation in chronic lymphocytic leukemia. Vidaza, a DNA methylation inhibitor, is already approved for treatment of patients with myelodysplastic syndrome. This study proposes to study if Vidaza is an effective DNA methylation inhibitor in patients with chronic lymphocytic leukemia.